These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 18774696)

  • 1. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study.
    Hawkins KA; Keefe RS; Christensen BK; Addington J; Woods SW; Callahan J; Zipursky RB; Perkins DO; Tohen M; Breier A; McGlashan TH
    Schizophr Res; 2008 Oct; 105(1-3):1-9. PubMed ID: 18774696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
    Keefe RS; Seidman LJ; Christensen BK; Hamer RM; Sharma T; Sitskoorn MM; Lewine RR; Yurgelun-Todd DA; Gur RC; Tohen M; Tollefson GD; Sanger TM; Lieberman JA
    Am J Psychiatry; 2004 Jun; 161(6):985-95. PubMed ID: 15169686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.
    Keefe RS; Sweeney JA; Gu H; Hamer RM; Perkins DO; McEvoy JP; Lieberman JA
    Am J Psychiatry; 2007 Jul; 164(7):1061-71. PubMed ID: 17606658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic drug effects on brain morphology in first-episode psychosis.
    Lieberman JA; Tollefson GD; Charles C; Zipursky R; Sharma T; Kahn RS; Keefe RS; Green AI; Gur RE; McEvoy J; Perkins D; Hamer RM; Gu H; Tohen M;
    Arch Gen Psychiatry; 2005 Apr; 62(4):361-70. PubMed ID: 15809403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample.
    Miller TJ; Zipursky RB; Perkins D; Addington J; Woods SW; Hawkins KA; Hoffman R; Preda A; Epstein I; Addington D; Lindborg S; Marquez E; Tohen M; Breier A; McGlashan TH
    Schizophr Res; 2003 May; 61(1):19-30. PubMed ID: 12648732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis.
    McGlashan TH; Zipursky RB; Perkins D; Addington J; Miller T; Woods SW; Hawkins KA; Hoffman RE; Preda A; Epstein I; Addington D; Lindborg S; Trzaskoma Q; Tohen M; Breier A
    Am J Psychiatry; 2006 May; 163(5):790-9. PubMed ID: 16648318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
    Goldberg TE; Goldman RS; Burdick KE; Malhotra AK; Lencz T; Patel RC; Woerner MG; Schooler NR; Kane JM; Robinson DG
    Arch Gen Psychiatry; 2007 Oct; 64(10):1115-22. PubMed ID: 17909123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cognitive deficits in first episode psychosis patients and people at risk for psychosis: from diagnosis to treatment].
    Lecardeur L; Meunier-Cussac S; Dollfus S
    Encephale; 2013 May; 39 Suppl 1():S64-71. PubMed ID: 23528322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia.
    Goldberg TE; Burdick KE; McCormack J; Napolitano B; Patel RC; Sevy SM; Goldman R; Lencz T; Malhotra AK; Kane JM; Robinson DG
    Schizophr Res; 2009 Feb; 107(2-3):262-6. PubMed ID: 19042105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive efficacy of quetiapine and olanzapine in early-onset first-episode psychosis.
    Robles O; Zabala A; Bombín I; Parellada M; Moreno D; Ruiz-Sancho A; Arango C
    Schizophr Bull; 2011 Mar; 37(2):405-15. PubMed ID: 19706697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurocognitive impairments in individuals at ultra-high risk for psychosis: Who will really convert?
    Bang M; Kim KR; Song YY; Baek S; Lee E; An SK
    Aust N Z J Psychiatry; 2015 May; 49(5):462-70. PubMed ID: 25425742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropsychological dysfunction in antipsychotic-naive first-episode unipolar psychotic depression.
    Hill SK; Keshavan MS; Thase ME; Sweeney JA
    Am J Psychiatry; 2004 Jun; 161(6):996-1003. PubMed ID: 15169687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
    Harvey PD; Rabinowitz J; Eerdekens M; Davidson M
    Am J Psychiatry; 2005 Oct; 162(10):1888-95. PubMed ID: 16199835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis.
    Seidman LJ; Giuliano AJ; Meyer EC; Addington J; Cadenhead KS; Cannon TD; McGlashan TH; Perkins DO; Tsuang MT; Walker EF; Woods SW; Bearden CE; Christensen BK; Hawkins K; Heaton R; Keefe RS; Heinssen R; Cornblatt BA;
    Arch Gen Psychiatry; 2010 Jun; 67(6):578-88. PubMed ID: 20530007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Keefe RS; Bilder RM; Davis SM; Harvey PD; Palmer BW; Gold JM; Meltzer HY; Green MF; Capuano G; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Davis CE; Hsiao JK; Lieberman JA; ;
    Arch Gen Psychiatry; 2007 Jun; 64(6):633-47. PubMed ID: 17548746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates.
    Bilder RM; Goldman RS; Robinson D; Reiter G; Bell L; Bates JA; Pappadopulos E; Willson DF; Alvir JM; Woerner MG; Geisler S; Kane JM; Lieberman JA
    Am J Psychiatry; 2000 Apr; 157(4):549-59. PubMed ID: 10739413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
    Buchanan RW; Javitt DC; Marder SR; Schooler NR; Gold JM; McMahon RP; Heresco-Levy U; Carpenter WT
    Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study.
    Poyurovsky M; Faragian S; Fuchs C; Pashinian A
    Isr J Psychiatry Relat Sci; 2009; 46(3):213-20. PubMed ID: 20039523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol.
    Sergi MJ; Green MF; Widmark C; Reist C; Erhart S; Braff DL; Kee KS; Marder SR; Mintz J
    Am J Psychiatry; 2007 Oct; 164(10):1585-92. PubMed ID: 17898351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in neurocognitive functioning during transition to manifest disease: comparison of individuals at risk for schizophrenic and bipolar affective psychoses.
    Metzler S; Dvorsky D; Wyss C; Müller M; Gerstenberg M; Traber-Walker N; Walitza S; Theodoridou A; Rössler W; Heekeren K
    Psychol Med; 2015 Jul; 45(10):2123-34. PubMed ID: 25640248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.